Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals.
作者信息
Allen Niamh, Brady Melissa, Carrion Martin Antonio Isidro, Domegan Lisa, Walsh Cathal, Doherty Lorraine, Riain Una Ni, Bergin Colm, Fleming Catherine, Conlon Niall
机构信息
Department of GU Medicine and Infectious Diseases (GUIDE), St. James's Hospital, Dublin, Ireland.
European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, (ECDC), Stockholm, Sweden; Health Protection Surveillance Centre (HPSC), Dublin, Ireland.
出版信息
J Infect. 2021 Oct;83(4):e9-e10. doi: 10.1016/j.jinf.2021.08.012. Epub 2021 Aug 9.
Abstract
摘要
相似文献
1
Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals.
J Infect. 2021 Oct;83(4):e9-e10. doi: 10.1016/j.jinf.2021.08.012. Epub 2021 Aug 9.
2
SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Microbiol Spectr. 2021 Oct 31;9(2):e0039121. doi: 10.1128/Spectrum.00391-21. Epub 2021 Sep 29.
3
SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 - April 2021.
Am J Emerg Med. 2022 Apr;54:81-86. doi: 10.1016/j.ajem.2022.01.055. Epub 2022 Feb 2.
4
SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study.
Viruses. 2022 Sep 4;14(9):1966. doi: 10.3390/v14091966.
5
Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Microbiol Spectr. 2021 Oct 31;9(2):e0008721. doi: 10.1128/Spectrum.00087-21. Epub 2021 Sep 1.
6
Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.
J Infect Dis. 2020 Jun 29;222(2):206-213. doi: 10.1093/infdis/jiaa273.
7
A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
Microbiol Spectr. 2021 Oct 31;9(2):e0069321. doi: 10.1128/Spectrum.00693-21. Epub 2021 Sep 15.
8
A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
Microbiol Spectr. 2021 Oct 31;9(2):e0087021. doi: 10.1128/Spectrum.00870-21. Epub 2021 Oct 6.
9
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
10
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
mSphere. 2021 Feb 24;6(1):e01145-20. doi: 10.1128/mSphere.01145-20.
引用本文的文献
1
Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.
J Infect Dis. 2025 Aug 14;232(2):e327-e340. doi: 10.1093/infdis/jiaf246.
2
BA.1 breakthrough infection elicits distinct antibody and memory B cell responses in vaccinated-only versus hybrid immunity individuals.
iScience. 2025 Feb 5;28(4):111962. doi: 10.1016/j.isci.2025.111962. eCollection 2025 Apr 18.
3
Association of infection-induced antibody levels with risk of subsequent SARS-COV-2 reinfection among healthcare professionals, Rhode Island, 1 March 2020-17 February 2021.
Microbiol Spectr. 2025 Apr;13(4):e0208624. doi: 10.1128/spectrum.02086-24. Epub 2025 Feb 25.
4
Vaccination caused an underestimation of the cumulative incidence of SARS-CoV-2 infection.
Microbiol Spectr. 2025 Feb 4;13(2):e0155824. doi: 10.1128/spectrum.01558-24. Epub 2024 Dec 16.
5
Incidence of SARS-CoV-2 during the Omicron wave: Results of a longitudinal serosurvey in Québec, Canada.
Can J Public Health. 2024 Dec;115(6):946-952. doi: 10.17269/s41997-024-00918-1. Epub 2024 Jul 26.
6
Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study.
Nat Commun. 2023 Nov 27;14(1):7764. doi: 10.1038/s41467-023-43330-y.
7
Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein.
Sci Rep. 2023 Oct 26;13(1):18394. doi: 10.1038/s41598-023-45718-8.
8
Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.
iScience. 2023 Jul 21;26(7):107056. doi: 10.1016/j.isci.2023.107056. Epub 2023 Jun 7.
9
Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2.
Sci Rep. 2023 Mar 27;13(1):4961. doi: 10.1038/s41598-023-31114-9.
10
Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.
J Transl Med. 2023 Feb 14;21(1):123. doi: 10.1186/s12967-023-03963-5.
本文引用的文献
1
Identification of Natural SARS-CoV-2 Infection in Seroprevalence Studies Among Vaccinated Populations.
Mayo Clin Proc. 2022 Apr;97(4):754-760. doi: 10.1016/j.mayocp.2022.02.002. Epub 2022 Feb 14.
2
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Clin Microbiol Infect. 2021 Oct;27(10):1516.e7-1516.e14. doi: 10.1016/j.cmi.2021.05.041. Epub 2021 Jun 7.
3
Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021.
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.04.037. Epub 2021 May 11.
4
Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays.
Diagnostics (Basel). 2021 Mar 3;11(3):426. doi: 10.3390/diagnostics11030426.
5
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3.
6
SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients.
Sci Rep. 2020 Oct 6;10(1):16561. doi: 10.1038/s41598-020-73491-5.
7
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.
Emerg Infect Dis. 2020 Jul;26(7):1478-1488. doi: 10.3201/eid2607.200841. Epub 2020 Jun 21.
Zotero 插件